Xinnate key facts
as of Oct 2026- Developer of a biopharmaceutical platform intended to develop proprietary peptides for the prevention and treatment of wounds and topical applications.
- Xinnate is valued at approximately $38.8M as of Oct 2026 (last reported valuation).
- It has raised $16.1M; the latest was Later Stage VC ($3.2M) in Jul 2025.
- Notable investors include United States Department of War, Jinderman & Partners, SmiLe Incubator, Swedish Research Council.
- Status: Privately Held (backing).
Xinnate's last reported valuation, Dec 2022. Nothing priced has surfaced since.
- ·Watch Xinnate: the Monday email on marks, rounds and moves
Xinnate funding rounds
No funding rounds for Xinnate are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Xinnate valuation
Xinnate's last reported valuation was $38.8 million in Dec 2022. No priced round, secondary trade or fund mark has surfaced since.
Xinnate investors
4 investors are on record for Xinnate, including United States Department of War, Jinderman & Partners, SmiLe Incubator and Swedish Research Council.
About Xinnate
Developer of a biopharmaceutical platform intended to develop proprietary peptides for the prevention and treatment of wounds and topical applications. The company's platform develops products based on one of the natural defense mechanisms that have been shown to have a sustainable anti-inflammatory and antibacterial effect regardless of multi-resistance, enabling the pharmaceutical industry to get functionalized biomaterials and cost-efficient treatment in a growing market of wounds and surgery.
- Sector
- Healthcare
- HQ
- Lund, Sweden
- Founded
- 2019
- Employees
- 7
- Website
- xinnate.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.